<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management - adults | Management | Diabetes - type 2 | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the primary care management of adults with type 2 diabetes."/><meta data-react-helmet="true" property="og:description" content="Covers the primary care management of adults with type 2 diabetes."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/diabetes-type-2/management/management-adults/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management - adults | Management | Diabetes - type 2 | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/diabetes-type-2/management/management-adults/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Diabetes - type 2</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management - adults</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/diabetes-type-2/","name":"Diabetes - type 2"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/diabetes-type-2/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management - adults"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Diabetes - type 2: </span><span>Scenario: Management - adults</span></h1><p class="page-header__lead"><span>Last revised in January 2021</span></p></div><p class="visually-hidden">Covers the primary care management of adults with type 2 diabetes.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Diabetes - type 2 chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - adults"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - adults</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - children and young people"><a aria-current="false" href="../management-children-young-people/index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - children and young people</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#initial-information-advice">Initial information and advice</a><ol aria-label="Sections within Initial information and advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-822">Basis for recommendation</a></li></ol></li><li><a href="index.html#treatment-targets">Treatment targets</a><ol aria-label="Sections within Treatment targets" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-9f4">Basis for recommendation</a></li></ol></li><li><a href="index.html#antidiabetic-drugs">Antidiabetic drugs</a><ol aria-label="Sections within Antidiabetic drugs" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-670">Basis for recommendation</a></li></ol></li><li><a href="index.html#lifestyle-advice">Lifestyle advice</a><ol aria-label="Sections within Lifestyle advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#diet">Diet</a></li><li class=""><a href="index.html#exercise-physical-activity">Exercise and physical activity</a></li><li class=""><a href="index.html#alcohol-intake">Alcohol intake</a></li><li class=""><a href="index.html#smoking-drug-misuse">Smoking and drug misuse</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ce0">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-suspected-hyperglycaemic-emergencies-dka-hhs">Managing suspected hyperglycaemic emergencies (DKA and HHS)</a><ol aria-label="Sections within Managing suspected hyperglycaemic emergencies (DKA and HHS)" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-78f">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-intercurrent-illness">Managing intercurrent illness</a><ol aria-label="Sections within Managing intercurrent illness" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#sick-day-rules">&#x27;Sick-day rules&#x27;</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-d44">Basis for recommendation</a></li></ol></li><li><a href="index.html#screening-for-managing-complications">Screening for and managing complications</a><ol aria-label="Sections within Screening for and managing complications" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#retinopathy">Retinopathy</a></li><li class=""><a href="index.html#foot-problems">Foot problems</a></li><li class=""><a href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a></li><li class=""><a href="index.html#cardiovascular-risk-factors">Cardiovascular risk factors</a></li><li class=""><a href="index.html#peripheral-autonomic-neuropathy">Peripheral and autonomic neuropathy</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-594">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-cardiovascular-risk">Managing cardiovascular risk</a><ol aria-label="Sections within Managing cardiovascular risk" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#antihypertensive-treatment">Antihypertensive treatment</a></li><li class=""><a href="index.html#lipid-modification">Lipid modification</a></li><li class=""><a href="index.html#antiplatelet-treatment">Antiplatelet treatment</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-c62">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management-adults" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management-adults" class="visually-hidden">Scenario: Management - adults</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d373871a-48cb-4588-a34d-bd7a72e03508 --><!-- begin field 8d296058-a320-4583-8e2d-acd900ac8bb0 --><p>From age 18 years onwards.</p><!-- end field 8d296058-a320-4583-8e2d-acd900ac8bb0 --><!-- end item d373871a-48cb-4588-a34d-bd7a72e03508 --></div><section aria-labelledby="initial-information-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-information-advice">What initial information and advice should I offer an adult with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b026d26b-013c-483b-b2c8-7d521d9f99e3 --><!-- begin field 852cb128-2012-4388-8370-202769db19d8 --><p><strong>Ensure that the person has an individualized care plan, taking into account their age, preferences, co-morbidities, and risk of adverse effects from medication.</strong></p><ul><li>Offer referral to a structured group education programme such as the DESMOND (Diabetes Education for Self-Management for Ongoing and Newly Diagnosed) programme, for the person and their family/carers.<ul><li>This should be offered at or around the time of diagnosis, with annual reinforcement and review.</li><li>Advise that the website <a href="https://www.desmond.nhs.uk/" data-hyperlink-id="ab02e822-1b23-4191-b2f0-aca0010f7751">www.desmond.nhs.uk</a> may have useful information.</li></ul></li><li>Ensure that the person and their family/carers know how to contact the specialist diabetes team, if appropriate.</li><li>Provide advice on sources of information and support.<ul><li>Diabetes UK (website available at <a href="https://www.diabetes.org.uk/" data-hyperlink-id="12c79d7a-5ed3-4d72-85cd-aca0010ea22e">www.diabetes.org.uk</a>) — a national charity that provides information, support, and advocacy for people with diabetes and their families. It has a confidential helpline (0345 123 2399) and hosts an online community for peer support, as well as a wide range of education and information <a href="https://www.diabetes.org.uk/professionals/information-support-for-your-patients/education-information" data-hyperlink-id="6f592ab1-35c2-4076-ad58-aca0010ea22e">patient resources</a>.</li><li>For detailed information on managing other lifestyle and cultural issues, such as driving, fasting, holiday and travel, insurance, and shift work, see the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a>.</li></ul></li><li>Provide advice on <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">lifestyle measures</a>, such as diet, exercise, and weight loss, if appropriate.</li><li>Assess for associated anxiety and depression, and manage appropriately. See the CKS topics on <a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a> and <a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a> for more information.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/emotions" data-hyperlink-id="243379d2-bb94-4e19-927b-aca1011426cd">Diabetes and your emotions</a> may be helpful.</li></ul></li><li>Advise about sexual health, contraception, and the importance of pre-pregnancy counselling, if appropriate. See the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a> and <a class="topic-reference external-reference" href="../../../../pre-conception-advice-and-management.html">Pre-conception - advice and management</a> for more information.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/pregnancy" data-hyperlink-id="3cccaeca-f21c-47a1-8980-aca1011426cd">Planning for a pregnancy when you have diabetes</a> may be helpful.</li></ul></li><li>Offer immunization against influenza and pneumococcal infection. See the CKS topics on <a class="topic-reference external-reference" href="../../../immunizations-seasonal-influenza/index.html">Immunizations - seasonal influenza</a> and <a class="topic-reference external-reference" href="../../../immunizations-pneumococcal/index.html">Immunizations - pneumococcal</a> for more information.</li><li>Advise about entitlement to free NHS prescriptions if the person uses insulin or antidiabetic medication. See the Diabetes UK section on <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/free-prescriptions" data-hyperlink-id="9a2319a8-4fae-4ae5-a282-aca0010ea22e">Free prescriptions (England)</a> for more information.</li><li>Advise the person to always wear or carry some form of diabetes identification, such as a:<ul><li>MedicAlert® bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="a38fa5f2-eb5d-4714-ab9c-a93100c1faba">www.medicalert.org.uk</a>).</li><li>Diabetes identity card or wristband (available from <a href="https://www.diabetes.org.uk/" data-hyperlink-id="77e582d5-998c-420a-9c7f-aca0010ea22e">www.diabetes.org.uk</a>).</li></ul></li><li>Advise that HbA1c should be measured at 3–6 monthly intervals initially until stable on unchanging antidiabetic treatment, and then every 6 months to ensure adequate blood glucose control. See the section on <a class="topic-reference internal-reference" href="index.html#treatment-targets">Treatment targets</a> for more information.</li><li>Advise that <a class="topic-reference internal-reference" href="index.html#screening-for-managing-complications">screening for complications</a> will be arranged at diagnosis and then annually thereafter.</li></ul><!-- end field 852cb128-2012-4388-8370-202769db19d8 --><!-- end item b026d26b-013c-483b-b2c8-7d521d9f99e3 --></div><section aria-labelledby="basis-for-recommendation-822" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-822">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 82203acf-29c5-4a8c-b441-fbf8c56e5b28 --><!-- begin field 923a0c9b-3523-49d3-a184-cae3e6e3e592 --><p>The recommendations on initial information and advice are largely based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and <em>Hypertension in adults: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>], the joint European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) publication <em>ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>], the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>], and expert opinion in a review article on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</p><ul><li>The NICE clinical guideline recommends an individualized approach to diabetes care that is tailored to the needs and circumstances of each person, and stresses the importance of patient education and self-management for optimal diabetes care [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>]. The ADA/EASD consensus report recommends a patient-centred approach to enhance engagement in self-care activities, with individualized treatment goals and strategies [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>]. This approach is further supported by the joint ESC/EASD guidelines that highlight the importance of patient-centred care to allow shared decision-making, and to empower and encourage the person to self-care, taking into account the person's wishes and goals, based on limited evidence and consensus opinion [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li><li>The recommendation to refer to a structured education programme to provide knowledge and skills to self-manage diabetes is largely based on limited evidence and the clinical expertise of the NICE guideline development group, which concluded well-designed and well-implemented programmes were likely to be clinically- and cost-effective interventions [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>The NICE guideline development group noted evidence from the DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) study that showed changes in health beliefs, reduction in depression, increases in self-reported physical activity and weight reduction, and improvement in smoking status following engagement with the programme.</li><li>Similarly, the ADA/EASD consensus report recommends all people with type 2 diabetes are offered access to an educational programme (DESMOND or equivalent), to allow people to make informed decisions and take responsibility for self-care. It cites evidence that such programmes improve blood glucose control, clinical outcomes, reduce hospital admissions, and reduce the risk of all-cause mortality [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].</li><li>The joint ESC/EASD guidelines also recommend referral for group-based structured education programmes, as there is evidence these improve disease knowledge, blood glucose control, disease management, and empower people with diabetes to manage their condition, based on data derived from multiple randomized controlled trials or meta-analyses [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li></ul></li><li>The recommendation to provide advice on lifestyle measures is extrapolated from the NICE clinical guideline on hypertension [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>].</li><li>The recommendation to assess for anxiety and depression is based on expert opinion in a review article, which highlights the importance of psychological and emotional wellbeing in helping engagement with behaviour and lifestyle change, self-management, and adherence to medication regimens [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The recommendation to advise about contraception and pre-pregnancy counselling is extrapolated from expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The recommendation to offer influenza and pneumococcal immunization is based on expert opinion in a review article, which notes people with diabetes are at increased risk for severe complications from influenza infection [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li></ul><!-- end field 923a0c9b-3523-49d3-a184-cae3e6e3e592 --><!-- end item 82203acf-29c5-4a8c-b441-fbf8c56e5b28 --></div></section></section><section aria-labelledby="treatment-targets" class="ChapterBody-module--wrapper--2HCfk "><h3 id="treatment-targets">What are the treatment targets for adults with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b79a82d5-6faa-4e0b-8526-10d7aaf1c2e7 --><!-- begin field f34a24c8-99a5-440a-8aed-7e59ec63b5c2 --><p><strong>Offer <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">lifestyle advice</a> and <a class="topic-reference internal-reference" href="index.html#antidiabetic-drugs">drug treatment(s)</a> to achieve </strong><strong>an individualized target HbA1c level, to minimize the risk of long-term <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a>, depending on the person's age, preferences, risk of adverse effects, and co-morbidities.</strong></p><ul><li><strong>Educate the person about their individual recommended HbA1c target, and encourage measures to achieve and maintain it, where possible.</strong><br><ul><li>Lifestyle including diet management — 48 mmol/mol (6.5%).</li><li>Lifestyle including diet combined with a single drug not associated with hypoglycaemia (such as metformin) — 48 mmol/mol (6.5%).</li><li>Drug treatment associated with hypoglycaemia (such as a sulfonylurea): 53 mmol/mol (7.0%).</li></ul></li><li><strong>Measure HbA1c levels at 3–6 monthly intervals until the HbA1c is stable on unchanging treatment, then at 6-monthly intervals.</strong></li><li><strong>If HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol/mol (7.5%) or higher:</strong><ul><li>Reinforce advice on lifestyle including diet.</li><li>Assess the person's adherence to antidiabetic drug treatment.</li><li>Support the person to aim for an HbA1c level of 53 mmol/mol (7.0%).</li><li>Intensify antidiabetic drug treatment, if appropriate. See the section on <a class="topic-reference internal-reference" href="index.html#antidiabetic-drugs">Antidiabetic drugs</a> for more information.</li></ul></li><li><strong>HbA1c targets should be individualized according to</strong> the person's duration of diabetes, co-morbidities, and age, and may be reduced if:<ul><li>There are adverse effects from treatment (such as hypoglycaemia), or treatment is affecting the person's quality of life.<ul><li>Tight blood glucose control and possible hypoglycaemia may be inappropriate for people at risk of falls, those with impaired awareness of hypoglycaemia, and people who drive or operate machinery.</li></ul></li><li>The person is unlikely to achieve longer-term risk-reduction benefits, for example if they have significant co-morbidities or a reduced life expectancy.</li></ul></li><li><strong>If the person achieves an HbA1c level that is lower than their target</strong> and there are no adverse effects such as hypoglycaemia:<ul><li>Encourage them to maintain it.</li><li>Be aware of alternative reasons for a low HbA1c level, such as deteriorating renal function or sudden weight loss. See the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information.</li><li>Consider stopping any medication that is not effective at review.</li></ul></li><li><strong>Do not routinely recommend self-monitoring of blood glucose levels.</strong><ul><li>Advise the person on the need to self-monitor blood glucose levels if they:<ul><li>Are using insulin therapy. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information.</li><li>Have evidence of hypoglycaemic episodes.</li><li>Are taking a drug that may increase the risk of hypoglycaemia while driving or operating machinery (such as a sulfonylurea). </li><li>Are pregnant or planning a pregnancy. See the CKS topic on <a class="topic-reference external-reference" href="../../../../pre-conception-advice-and-management.html">Pre-conception - advice and management</a> for more information.</li><li>Note: advise that blood glucose levels may increase with acute intercurrent illness or infection. See the section on <a class="topic-reference internal-reference" href="index.html#managing-intercurrent-illness">Managing intercurrent illness</a> for more information.</li></ul></li><li>Provide appropriate advice on driving if the person is self-monitoring blood glucose levels.<ul><li>See the Driver and Vehicle Licensing Agency (DVLA) document <a href="https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals" data-hyperlink-id="0a6857db-b1d0-4652-8678-ac9a00a20149">Assessing fitness to drive: a guide for medical professionals</a> for more information.</li></ul></li><li>Consider the need for short-term self-monitoring of blood glucose levels:<ul><li>When starting treatment with corticosteroids, <em>or</em></li><li>To confirm suspected <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a>.</li></ul></li></ul></li><li><strong>If routine self-monitoring of blood glucose levels is indicated,</strong> review the person at least annually to check:<ul><li>Self-monitoring skills, the quality and frequency of testing, and the equipment used. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for information on blood glucose meters, lancets, and strips.</li><li>The person knows how to interpret blood glucose results, and what action to take if they are too high or too low.</li><li>The impact of self-monitoring on the person's quality of life and the continued benefit to the person. </li></ul></li></ul><!-- end field f34a24c8-99a5-440a-8aed-7e59ec63b5c2 --><!-- end item b79a82d5-6faa-4e0b-8526-10d7aaf1c2e7 --></div><section aria-labelledby="basis-for-recommendation-9f4" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-9f4">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9f4c3038-a852-41ad-9515-7a71d81fbba6 --><!-- begin field 8f3b412b-a64d-4ac8-ab89-f0e793335c45 --><p>The recommendations on treatment targets are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], the joint European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) publication <em>ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>], the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>], and expert opinion in a review article on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</p><h5>HbA1c target levels</h5><ul><li>The recommendation to individualize HbA1c treatment targets is largely based on the NICE guideline development group, which reviewed the available evidence to determine the optimal target HbA1c level for adults with type 2 diabetes and the effects of different HbA1c levels on mortality risk and the risk of developing microvascular and macrovascular complications. The recommendations on the time intervals for checking HbA1c levels and action to take if targets are not met are also based on the NICE clinical guideline. It found [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>]: <ul><li>Moderate-quality evidence from one study that the risk for microvascular complications increased significantly with HbA1c levels above 48 mmol/mol (6.5%), and the risk for mortality and macrovascular complications increased significantly with HbA1c levels above 53 mmol/mol (7%). </li><li>Moderate- to high-quality evidence showed that all-cause mortality risk increased with increasing baseline levels of HbA1c.</li><li>Very low- to high-quality evidence showed that rising levels of HbA1c increased the risk of mortality and of developing macrovascular and microvascular complications, with critical thresholds ranging from 42–53 mmol/mol (6.0–7.0%).</li></ul></li><li>The NICE guideline development group recognized the trade-off between the increased benefits of setting target values for blood glucose to protect against long-term complications, and the possible associated harms, such as hypoglycaemia. Based on the evidence identified, it agreed that [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>]:<ul><li>A mid-range value of 48 mmol/mol (6.5%) would be achievable for most adults with type 2 diabetes who are managed by lifestyle and diet and/or one oral antidiabetic drug not associated with hypoglycaemia.  </li><li>Antidiabetic drug treatment should be intensified if HbA1c levels rise to 58 mmol/mol (7.5%), and considering the risk of hypoglycaemia, a realistic target of 53 mmol/mol (7.0%) should be set to achieve blood glucose control. </li><li>Special consideration of appropriate target values should be given to people at risk of hypoglycaemia, to achieve an acceptable balance between good blood glucose control and the likely negative impact on quality of life of this adverse effect.</li></ul></li><li>The joint ESC/EASD guidelines also highlight that blood glucose control to a target less than 53 mmol/mol decreases the risk of microvascular complications in people with diabetes, based on data derived from multiple randomized controlled trials or meta-analyses. In addition, it recommends this target should be considered for the prevention of macrovascular complications but notes that the evidence for this is less compelling than for microvascular complications. It also recognizes the need to individualize blood glucose targets in the elderly, people with frailty, and/or multiple co-morbidities, based on limited evidence and consensus opinion [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li><li>The ADA/EASD consensus report also states that optimal blood glucose control reduces the onset and progression of microvascular complications and highlights the need to individualize targets based on the person's preferences, risk of adverse effects, frailty, and co-morbid conditions. If treatment targets are not reached, it re-emphasizes the importance of lifestyle measures, assessing adherence to treatment, and arranging timely follow up [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>]. </li></ul><h5>Self-monitoring of blood glucose levels</h5><ul><li>The NICE guideline development group noted that while self-monitoring of blood glucose levels provides the potential for tight control and reduced risk of complications, the possible impact on hypoglycaemic episodes is important in determining its safety and acceptability [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>It found generally low-quality evidence that although a statistically significant difference was observed in HbA1c levels in favour of self-monitoring, the small reduction of less than 5 mmol/mol (0.5%; the threshold for minimal important difference) was not clinically significant. It therefore agreed that self-monitoring was not beneficial to people with type 2 diabetes, except certain groups of people, such as those using insulin therapy. </li><li>It highlighted clinical scenarios that may benefit from short-term self-monitoring of blood glucose, such as when starting corticosteroid treatment, but found no evidence that such monitoring is beneficial for people with acute intercurrent illness or infection, however, it highlighted the potential risk for worsening hyperglycaemia in these scenarios.</li><li>It recommended the need for regular review if a person is self-monitoring blood glucose levels but found inadequate evidence to make any recommendations on the frequency of self-monitoring, or on specific target values for people with type 2 diabetes.</li></ul></li><li>The joint ESC/EASD guidelines also recommend the use of structured self-monitoring of blood glucose level to optimize blood glucose control, if needed [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li></ul><!-- end field 8f3b412b-a64d-4ac8-ab89-f0e793335c45 --><!-- end item 9f4c3038-a852-41ad-9515-7a71d81fbba6 --></div></section></section><section aria-labelledby="antidiabetic-drugs" class="ChapterBody-module--wrapper--2HCfk "><h3 id="antidiabetic-drugs">Which antidiabetic drugs are available for adults with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f151f7ed-4b2a-41fb-a1c5-1bd8402b0d79 --><!-- begin field fbcb2d2c-e38a-4d1a-8754-ac7d00eede8e --><p><strong>If an adult with type 2 diabetes is hyperglycaemic with <strong><a class="topic-reference internal-reference" href="../../diagnosis/diagnosis-in-adults/index.html">symptoms</a></strong>, consider the need for immediate insulin therapy or treatment with a sulfonylurea depending on specialist advice, and review treatment when blood glucose control has been achieved.</strong> </p><p><strong>For all other adults, offer individualized antidiabetic treatment depending on the person's HbA1c <a class="topic-reference internal-reference" href="index.html#treatment-targets">treatment target</a>, age, preferences, co-morbidities, risks and benefits of treatment, and other drug treatments.</strong></p><ul><li><strong>Offer standard-release metformin as initial treatment, unless it is contraindicated.</strong><ul><li>Gradually increase the dose of standard-release <a class="topic-reference internal-reference" href="../../prescribing-information/metformin/index.html">metformin</a> over several weeks to minimize the risk of adverse effects.<ul><li>If there are intolerable gastrointestinal adverse effects, consider a trial of modified-release metformin.</li><li>Monitor renal function before and during treatment with metformin.</li></ul></li><li>If metformin is contraindicated or not tolerated, consider initial treatment with one of the following, unless contraindicated:<ul><li>A dipeptidyl peptidase-4 inhibitor (<a class="topic-reference internal-reference" href="../../prescribing-information/dpp-4-inhibitors/index.html">DPP-4 inhibitor</a>).</li><li><a class="topic-reference internal-reference" href="../../prescribing-information/pioglitazone/index.html">Pioglitazone</a>.</li><li>A <a class="topic-reference internal-reference" href="../../prescribing-information/sulfonylureas/index.html">sulfonylurea</a>.</li><li>A sodium-glucose cotransporter-2 inhibitor (<a class="topic-reference internal-reference" href="../../prescribing-information/sglt-2-inhibitors/index.html">SGLT-2 inhibitor</a>) may be considered instead of a DPP-4 inhibitor, if a sulfonylurea or pioglitazone is not appropriate.</li><li>Note: repaglinide (a meglitinide) is an alternative option, however there is no licensed non-metformin-based combination containing repaglinide that can be offered if second-line treatment is needed.</li></ul></li></ul></li><li><strong>If first-line treatment is <strong><a class="topic-reference internal-reference" href="index.html#treatment-targets">ineffective</a></strong>, consider one of the following second-line treatment options:</strong><ul><li>For people who can take metformin, consider dual therapy with: <ul><li>Metformin plus a DPP-4 inhibitor, <em>or</em></li><li>Metformin plus pioglitazone, <em>or</em></li><li>Metformin plus a sulfonylurea.</li><li>Metformin plus an SGLT-2 inhibitor may be considered if a sulfonylurea is contraindicated or not tolerated, or the person is at significant risk of hypoglycaemia or its consequences.</li></ul></li><li>For people in whom metformin is contraindicated or not tolerated, consider the following:<ul><li>A DPP-4 inhibitor plus pioglitazone, <em>or</em></li><li>A DPP-4 inhibitor plus a sulfonylurea, <em>or</em></li><li>Pioglitazone plus a sulfonylurea.</li></ul></li></ul></li><li><strong>If second-line treatment is<strong> <strong><a class="topic-reference internal-reference" href="index.html#treatment-targets">ineffective</a></strong>,</strong> consider one of the following third-line treatment options:</strong><ul><li>For people who can take metformin:<ul><li>Triple therapy with metformin, a DPP-4 inhibitor, and a sulfonylurea.</li><li>Triple therapy with metformin, pioglitazone, and a sulfonylurea.</li><li>Triple therapy with metformin, pioglitazone <em>or</em> a sulfonylurea, and the SGLT-2 inhibitors canagliflozin or empagliflozin. Note: the SGLT-2 inhibitor dapagliflozin is recommended only in combination with metformin and a sulfonylurea, <em>not</em> pioglitazone.</li><li>Triple therapy with metformin, a DPP-4 inhibitor, and the SGLT-2 inhibitor ertugliflozin, only if a sulfonylurea or pioglitazone is not appropriate.</li><li>Starting insulin-based treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information.</li></ul></li><li>For people in whom metformin is contraindicated or not tolerated:<ul><li>Consider starting insulin-based treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information.</li></ul></li></ul></li><li><strong>If third-line treatment is<strong><strong> <strong><a class="topic-reference internal-reference" href="index.html#treatment-targets">ineffective</a></strong>,</strong> </strong>not tolerated, or contraindicated:</strong><ul><li>For people on triple therapy with metformin and two other oral antidiabetic drugs, consider combination treatment with metformin, a sulfonylurea, and a glucagon-like peptide-1 receptor agonist (<a class="topic-reference internal-reference" href="../../prescribing-information/glp-1-receptor-agonists/index.html">GLP-1 receptor agonist</a>) for people with:<ul><li>A body mass index (BMI) of 35 kg/m<sup>2</sup> or higher (adjust accordingly for people from black, Asian, and other minority ethnic groups) and specific psychological or other medical conditions associated with obesity, <em>or</em></li><li>A BMI lower than 35 kg/m<sup>2</sup>, and insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related co-morbidities.</li><li>Note: a GLP-1 receptor agonist should only be continued if the person has shown a reduction of at least 11 mmol/mol [1.0%] in HbA1c <em>and</em> a weight loss of at least 3% of initial body weight in 6 months.</li></ul></li><li>For people on insulin-based treatment, arrange referral or seek advice from the specialist diabetes team, for consideration of treatment with a GLP-1 receptor agonist plus insulin.<ul><li>Note: if a GLP-1 receptor agonist is added to insulin or an insulin secretagogue (sulfonylurea or meglitinide), consider reducing the dose of the latter agents to reduce the risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a>. If a DPP-4 inhibitor is being taken, it should be discontinued on starting a GLP-1 receptor agonist, as the combination does not provide additional blood glucose control.</li></ul></li></ul></li></ul><!-- end field fbcb2d2c-e38a-4d1a-8754-ac7d00eede8e --><!-- end item f151f7ed-4b2a-41fb-a1c5-1bd8402b0d79 --></div><section aria-labelledby="basis-for-recommendation-670" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-670">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 67019772-a7b4-4ebe-b9b4-3ef12fa2fea5 --><!-- begin field ccbc6d0b-7e8f-406c-8457-0cb236a9e94c --><p>The recommendations on antidiabetic drugs are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], the NICE technology appraisal guidance <em>Canaglifozin, dapaglifozin and empaglifozin as monotherapies for treating type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>], <em>Canaglifozin in combination therapy for treating type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>], <em>Empaglifozin in combination therapy for treating type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>], <em>Dapaglifozin in combination therapy for treating type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>], <em>Dapaglifozin in triple therapy for treating type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016f</a>], and <em>Ertuglifozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019c</a>]. In addition, it is supported by the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>] and its 2019 update [<a class="bibliography-reference internal-reference" href="../../references/index.html">Buse, 2020</a>], the joint European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) publication <em>ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>], and expert opinion in review articles on SGLT-2 inhibitors [<a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2019</a>] and GLP-1 receptor agonists [<a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2020</a>].</p><h5>Immediate treatment with insulin or a sulfonylurea if symptomatic</h5><ul><li>The recommendation to consider the need for immediate treatment with insulin or a sulfonylurea if a person is hyperglycaemic with symptoms, is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and the consensus report by the ADA/EASD [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].</li></ul><h5>First-line treatment options</h5><ul><li>The recommendation to individualize drug treatment goals and regimens is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and the consensus report by the ADA/EASD [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].<ul><li>The NICE guideline development group assumed that augmenting existing drug treatments with additional drugs will provide better blood glucose control as the added drug will have a different mode of action.</li><li>The ADA/EASD consensus report recommends considering other co-morbidities such as cardiovascular disease (CVD), renal disease, obesity, and risk of hypoglycaemia, as well as safety, tolerability, and cost, before choosing an add-on therapy, to ensure the benefits outweigh potential harms.</li></ul></li><li>The recommendations to use standard-release metformin first line or modified-release metformin second line are based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and the consensus report by the ADA/EASD [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].<ul><li>The NICE guideline development group discussed that although standard-release metformin was not associated with the greatest reduction in HbA1c in the evidence review, its additional cardiovascular benefits, low likelihood of hypoglycaemic events, and associated weight loss at 12 and 24 months were considered important benefits of treatment.</li><li>The consensus report by the ADA/EASD notes metformin shows high efficacy, safety, tolerability, low cost, minimal hypoglycaemia risk when used as monotherapy, and the potential for some weight loss.</li></ul></li><li>The recommendations on alternative drug treatment options if metformin is contraindicated or not tolerated are based on the NICE clinical guideline, which noted a lack of specific data and extrapolated results from a network meta-analysis [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>The information on the option of using a SGLT-2 inhibitor is based on the NICE technology appraisal on SGLT-2 inhibitor monotherapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016d</a>].</li><li>CKS notes that the joint ESC/EASD publication recommends SGLT-2 inhibitors such as empagliflozin, canagliflozin, or dapagliflozin are used in people with type 2 diabetes and CVD or at very high/high risk of CVD, to reduce cardiovascular (CV) events. Empagliflozin is recommended in people with type 2 diabetes and CVD to reduce risk of death [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>]. In addition, the updated consensus report by the ADA/EASD recommends SLGT-2 inhibitor use for people with type 2 diabetes and heart failure to reduce the risk of hospitalization, major adverse CV events, and CV-related mortality, and their use in people with chronic kidney disease (CKD) to prevent progression of renal disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">Buse, 2020</a>].</li><li>The information that repaglinide may be considered as an alternative drug option is based on the NICE clinical guideline, which notes evidence for clinical- and cost-effectiveness, but limitations in options for drug intensification [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].</li></ul></li></ul><h5>Second-line treatment options</h5><ul><li>The recommendations on second-line treatment options with metformin are largely based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>Metformin plus a DPP-4 inhibitor was moderately effective in controlling blood glucose levels and was associated with fewer hypoglycaemic events and weight loss.</li><li>Metformin plus pioglitazone was most effective at reducing HbA1c levels at 24 months and preventing nausea but was associated with weight gain.</li><li>Metformin plus a sulfonylurea was moderately effective in reducing HbA1c levels but was strongly associated with more hypoglycaemic events.</li></ul></li><li>The recommendations on second-line treatment options when metformin is contraindicated or not tolerated are based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>The guideline development group found limited evidence for treatment intensification options for this group but noted that sitagliptin combined with a sulfonylurea was associated with high rankings in change in HbA1c at 6 months, and pioglitazone combined with a sulfonylurea was associated with weight gain at 24 months.</li></ul></li><li>The information on when metformin plus an SGLT-2 inhibitor can be considered in specific clinical situations is based on the NICE technology appraisals on SGLT-2 inhibitor combination therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016e</a>].</li></ul><h5>Third-line treatment options</h5><ul><li>The recommendations on third-line treatment options are based on limited evidence in the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>The guideline development group noted that non-insulin based triple therapy had limited impact on reducing HbA1c levels, but were associated with fewer hypoglycaemic events and, for some drug combinations, weight loss.</li><li>The information on when the SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin can be considered as part of triple therapy is based on the NICE technology appraisals on canagliflozin and empagliflozin combination therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015b</a>] and on dapagliflozin triple therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016f</a>].</li><li>The information on when the SGLT-2 inhibitor ertugliflozin can be considered as part of triple therapy is based on a NICE technology appraisal on ertugliflozin, which noted it has similar clinical benefits to other SGLT-2 inhibitors but has not been compared with sulfonylureas or pioglitazone as a third-line treatment option [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019c</a>].</li></ul></li></ul><h5>Further treatment intensification options</h5><ul><li>The information on the eligibility criteria for further intensification with a GLP-1 receptor agonist and the clinical criteria for continuing GLP-1 receptor agonist therapy is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>The NICE guideline development group considered GLP-1 receptor agonist therapy may be a cost-effective option for people with obesity who would require high doses of insulin, or for whom other treatment options were not tolerated or were contraindicated.</li><li>CKS notes that the updated consensus report by the ADA/EASD recommends that GLP-1 receptor agonists can be considered in people with type 2 diabetes without established CVD but at high risk of CVD, to reduce the risk of major adverse CV events, with the strongest evidence associated with dulaglutide. In addition, it recommends the use of GLP-1 receptor agonists or SLGT-2 inhibitors for high-risk people independent of HbA1c level or individualized HbA1c target [<a class="bibliography-reference internal-reference" href="../../references/index.html">Buse, 2020</a>].</li><li>CKS notes that the joint ESC/EASD publication recommends the GLP-1 receptor agonists liraglutide, semaglutide, or dulaglutide are considered in people with type 2 diabetes and CVD, or very high/high risk of CVD, to reduce CV events. Liraglutide is recommended in people with type 2 diabetes and CVD, or at very high/high risk of CVD, to reduce risk of death [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li><li>CKS notes that the consensus report by the ADA/EASD states that GLP-1 receptor agonists are an alternative to insulin initiation and may be considered first-line injectable therapy, with recognized benefit in people with established CVD, and additional potential benefits of weight loss and reduced risk of hypoglycaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].</li></ul></li><li>The recommendation to seek specialist advice before starting a GLP-1 receptor agonist plus insulin therapy is based on the NICE clinical guideline, which noted a lack of trial evidence for this treatment combination [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<ul><li>The information on the need to amend other antidiabetic drug treatment when starting a GLP-1 receptor agonist is based on expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2020</a>].</li></ul></li></ul><!-- end field ccbc6d0b-7e8f-406c-8457-0cb236a9e94c --><!-- end item 67019772-a7b4-4ebe-b9b4-3ef12fa2fea5 --></div></section></section><section aria-labelledby="lifestyle-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="lifestyle-advice">What lifestyle advice should I give to adults with type 2 diabetes?</h3><section aria-labelledby="diet" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diet">Diet</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b2b9272b-3a29-46ba-a879-db1ef6da43d8 --><!-- begin field 69f310e5-6d76-42d0-b1ea-e23292f99d05 --><p><strong>Offer appropriate, individualized, and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.</strong></p><ul><li><strong>Emphasize the importance of a healthy, balanced diet:</strong><ul><li>Encourage high fibre, low-glycaemic-index sources of carbohydrate (such as fruit, vegetables, wholegrains, and pulses), low-fat dairy products, and oily fish.</li><li>Advise to control the intake of foods containing saturated and trans-fatty acids, high-sugar drinks, and foods high in salt content.</li><li>Individualize recommendations for carbohydrate and alcohol intake, and regular meal patterns, to reduce the risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a>, especially in people being treated with insulin or a <a class="topic-reference internal-reference" href="../../prescribing-information/sulfonylureas/index.html">sulfonylurea</a>. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information.</li><li>Advise that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowed, but care should be taken to avoid excess energy intake.</li><li>Discourage the use of foods marketed specifically for people with diabetes.</li><li>The Diabetes UK patient resources <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/whats-your-healthy-weight/lose-weight" data-hyperlink-id="e89a1e60-a659-47b8-9805-aca10114f0fc">Weight loss and diabetes</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/what-is-a-healthy-balanced-diet" data-hyperlink-id="2e53272c-402a-4a6a-b4fd-aca101158c4a">What is a healthy, balanced diet for diabetes?</a> may be helpful.</li></ul></li><li><strong>Integrate dietary advice with other aspects of lifestyle modification, such as exercise and weight loss, as appropriate.</strong><ul><li>If the person is overweight or obese, set an initial body weight loss target of 5–10% (smaller weight losses may still be beneficial). See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for further information on weight management.</li></ul></li></ul><!-- end field 69f310e5-6d76-42d0-b1ea-e23292f99d05 --><!-- end item b2b9272b-3a29-46ba-a879-db1ef6da43d8 --></div></section><section aria-labelledby="exercise-physical-activity" class="ChapterBody-module--wrapper--2HCfk "><h4 id="exercise-physical-activity">Exercise and physical activity</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ef8a2ad2-2b9d-4d24-8c62-911c4318c717 --><!-- begin field a5a0a348-7e16-4cd7-b194-9e82e1fa0389 --><ul><li><strong>Provide information on regular exercise and physical activity.</strong> <ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/exercise" data-hyperlink-id="57669314-88b0-4d1c-b2d7-aca1011eab2c">Diabetes and exercise</a> provides helpful information on the type and duration of recommended exercise.</li><li>Aim to minimize time spent being sedentary.</li><li>Advise that regular exercise may lower blood glucose levels, improve cardiovascular risk, and reduce excess weight (when combined with a <a class="topic-reference internal-reference" href="index.html#diet">healthy diet</a>). See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li><strong>Provide information on the following (if appropriate):</strong><ul><li>The potential interaction of exercise and alcohol.</li><li>The effect of exercise on blood glucose levels when insulin levels are adequate (risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a>). </li><li>The effect of exercise on blood glucose levels when the person is hyperglycaemic (risk of worsening blood glucose control and ketones in the blood).</li><li>The appropriate adjustments of insulin dosage and/or nutritional intake for exercise and post-exercise periods. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin in type 2 diabetes</a> for more information.</li></ul></li></ul><!-- end field a5a0a348-7e16-4cd7-b194-9e82e1fa0389 --><!-- end item ef8a2ad2-2b9d-4d24-8c62-911c4318c717 --></div></section><section aria-labelledby="alcohol-intake" class="ChapterBody-module--wrapper--2HCfk "><h4 id="alcohol-intake">Alcohol intake</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item df7346b2-7880-4096-9d1d-89296e77043c --><!-- begin field 5744bc78-444f-4c9b-b0d5-08313f67c9bc --><ul><li><strong>Provide information on recommended alcohol limits and the potential impact of alcohol on diabetes and its treatment.</strong><ul><li>Advise on the recommended alcohol limits. See CKS topic on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/index.html">Alcohol - problem drinking</a> for more information.</li><li>Advise the person to ideally eat a snack that contains carbohydrate before and after drinking alcohol. </li><li>Educate that alcohol may exacerbate or prolong the hypoglycaemic effect of <a class="topic-reference internal-reference" href="index.html#antidiabetic-drugs">antidiabetic drugs</a>.<ul><li>The signs of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a> may become less obvious, and delayed hypoglycaemia may occur up to several hours after alcohol consumption. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information on the possible presentation and effects of hypoglycaemia. </li></ul></li><li>Advise the person to always wear or carry some form of diabetes identification, as reduced awareness of hypoglycaemia may be confused with alcohol intoxication, such as a:<ul><li>MedicAlert® bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="a38fa5f2-eb5d-4714-ab9c-a93100c1faba">www.medicalert.org.uk</a>).</li><li>Diabetes identity card or wristband (available from <a href="https://www.diabetes.org.uk/" data-hyperlink-id="77e582d5-998c-420a-9c7f-aca0010ea22e">www.diabetes.org.uk</a>).</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/what-to-drink-with-diabetes/alcohol-and-diabetes" data-hyperlink-id="501c9556-7c37-4851-aac4-aca101432e59">Alcohol and diabetes</a> may be helpful.</li></ul></li></ul><!-- end field 5744bc78-444f-4c9b-b0d5-08313f67c9bc --><!-- end item df7346b2-7880-4096-9d1d-89296e77043c --></div></section><section aria-labelledby="smoking-drug-misuse" class="ChapterBody-module--wrapper--2HCfk "><h4 id="smoking-drug-misuse">Smoking and drug misuse</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 05e2e1e3-aa35-425c-a3a6-6c6228875ee8 --><!-- begin field 5c32b111-dae4-42c5-8214-9299dcf177c8 --><ul><li><strong>Provide information on the impact of smoking on diabetes and its complications, such as cardiovascular disease.</strong><ul><li>Advise on smoking cessation, if appropriate. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information. Reinforce this advice annually for people who currently do not plan to stop smoking, and at all review appointments if there is a prospect of the person stopping. </li><li>Advise young adult non-smokers never to start smoking.</li></ul></li><li><strong>Provide information on the risks of drug misuse and the possible effects on blood glucose control.</strong><ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/young-adults/drugs" data-hyperlink-id="2a0d660b-8822-4d73-aede-aca10142cf61">Recreational drugs and diabetes</a> may be helpful.</li></ul></li></ul><!-- end field 5c32b111-dae4-42c5-8214-9299dcf177c8 --><!-- end item 05e2e1e3-aa35-425c-a3a6-6c6228875ee8 --></div></section><section aria-labelledby="basis-for-recommendation-ce0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ce0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ce040329-849e-4bfb-8b3d-b3e156676d75 --><!-- begin field 3fd3578c-4f42-471a-8e4c-5f546d12e9a2 --><p>The recommendations on lifestyle advice are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>], the joint European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) publication <em>ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>], and expert opinion in a review article on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</p><h5>Advice on diet</h5><ul><li>The recommendations on dietary advice are largely based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].<br><ul><li>The NICE guideline development group suggested a healthy balanced diet can help to achieve and maintain blood glucose levels and blood pressure in the normal range (or as close to normal as is safely possible), and a lipid and lipoprotein profile that reduces the risk of vascular disease.</li><li>It recommended following the principles of healthy eating for the general population.</li><li>It discouraged the use of 'diabetic foods' because, although they may be low in sugars, most are high in calories and are therefore unsuitable as well as unnecessary for people who are overweight. Furthermore, it does not recommend low-carbohydrate or high-protein diets due to a lack of evidence of long-term safety, although the latter were acknowledged as being effective for short-term weight loss.</li></ul></li><li>The recommendations are also supported by the ADA/EASD consensus report [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>], the joint ESC/EASD publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].<ul><li>Lifestyle interventions including nutrition and physical activity are effective and safe strategies for improving blood glucose control and improving cardiovascular risk factors in people with type 2 diabetes and are recommended first line from the time of diagnosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].</li><li>Reduced calorie intake is recommended in people who are overweight or obese in people with diabetes, based on data derived from multiple randomized controlled trials (RCTs) or meta-analyses. In addition, a diet rich in polyunsaturated and monounsaturated fats should be considered, based on data derived from a single RCT or large non-randomized studies. Weight reduction and decreased consumption of fast-absorbed carbohydrates and alcohol can help lipid lowering, particularly in people with low HDL-C and high triglyceride levels, based on data derived from a single RCT or large non-randomized studies [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li><li>The recommendation to reduce salt intake is based on the joint ESC/EASD publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li></ul></li></ul><h5>Advice on exercise and physical activity</h5><ul><li>The recommendations on exercise and physical activity are based on the ADA/EASD consensus report [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>] and the joint ESC/EASD publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].<ul><li>Lifestyle interventions including nutrition and physical activity are effective and safe strategies for improving blood glucose control and improving cardiovascular risk factors in people with type 2 diabetes and are recommended first line from the time of diagnosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].</li><li>Moderate-to-vigorous physical activity as a combination of aerobic and resistance exercise for 150 minutes per week or more, is recommended in the joint ESC/EASD guidelines, based on data derived from multiple RCTs or meta-analyses, as there is evidence it improves blood glucose control, lipid levels, blood pressure, and cardiovascular complications [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li></ul></li></ul><h5>Advice on alcohol intake</h5><ul><li>The NICE clinical guideline recommends that people with type 2 diabetes who are overweight or prone to hypoglycaemia through use of insulin secretagogues (such as sulfonylureas) or insulin should be advised on alcohol intake [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>]. They are also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Advice on smoking and drug misuse</h5><ul><li>Smoking cessation is recommended in the joint ESC/EASD guidelines, based on data derived from multiple RCTs or meta-analyses, as it increases the risk of cardiovascular disease and premature death [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li><li>Expert opinion in a review article notes that smoking can also increase the risk of diabetic retinopathy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The recommendations on drug misuse are pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field 3fd3578c-4f42-471a-8e4c-5f546d12e9a2 --><!-- end item ce040329-849e-4bfb-8b3d-b3e156676d75 --></div></section></section><section aria-labelledby="managing-suspected-hyperglycaemic-emergencies-dka-hhs" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-suspected-hyperglycaemic-emergencies-dka-hhs">How should I manage an adult with a suspected hyperglycaemic emergency?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 623e7d60-d7b1-4369-a1bb-4a1c0d6265cc --><!-- begin field 03843634-79e4-490a-8dd3-85cbaed810c1 --><p><strong>Be aware that <strong><a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">diabetic ketoacidosis</a></strong></strong><strong> (DKA) is more common </strong><strong>i</strong><strong>n people with type 1 diabetes, but can occur in people with type 2 diabetes, and may present with a normal or near normal blood glucose level. <strong><a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">Hyperosmolar hyperglycaemic state</a></strong> (HHS) typically presents without significant blood or urinary ketones on testing.</strong></p><ul><li><strong>Arrange emergency admission for confirmation of the diagnosis and emergency treatment.</strong></li><li><strong>After the person has recovered from an episode of DKA or HHS:</strong><ul><li>Discuss the <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html#precipitating-factors">precipitating factors</a> that may have led to the episode. Consider the possibility of non-adherence to treatment, particularly if there is a history of recurrent DKA.</li><li>Provide information and advice about how to manage intercurrent illness and 'sick day rules', to reduce the risk of future episodes. See the section on <a class="topic-reference internal-reference" href="index.html#managing-intercurrent-illness">Managing intercurrent illness</a> for more information.</li></ul></li></ul><!-- end field 03843634-79e4-490a-8dd3-85cbaed810c1 --><!-- end item 623e7d60-d7b1-4369-a1bb-4a1c0d6265cc --></div><section aria-labelledby="basis-for-recommendation-78f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-78f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 78fb1e34-ce3d-46dc-b066-34c67dad7f4f --><!-- begin field 16566ae1-861b-4e05-8be3-e9aa2a30a61b --><p>The recommendations on management of suspected hyperglycaemic emergencies are extrapolated from the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], and are based on the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Diabetic ketoacidosis and the hyperglycemic hyperosmolar state</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>], and expert opinion in review articles on DKA and HHS [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>], on sick-day rules [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>], and on SGLT-2 inhibitors [<a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2019</a>].</p><ul><li>The information that diabetic ketoacidosis (DKA) may occur with normal or near normal blood glucose levels (euglycaemic DKA) is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2019</a>].</li><li>The information that hyperosmolar hyperglycaemic state (HHS) may occur without significant blood or urinary ketones is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>].</li><li>The recommendation to arrange emergency hospital admission for hyperglycaemic emergencies is based on the need for treatment with intravenous fluids to correct volume deficits and restore intravascular volume, replacement of electrolytes to correct abnormalities, correction of acidosis, and insulin infusion to treat hyperglycaemia (in the case of DKA) [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>].</li><li>The recommendation to identify precipitating factors and prevent recurrence by managing future intercurrent illness is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>] and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>].</li></ul><!-- end field 16566ae1-861b-4e05-8be3-e9aa2a30a61b --><!-- end item 78fb1e34-ce3d-46dc-b066-34c67dad7f4f --></div></section></section><section aria-labelledby="managing-intercurrent-illness" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-intercurrent-illness">How should I manage intercurrent illness in an adult with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cbd50e0c-1872-4d54-ae2e-65e05298a2af --><!-- begin field b598f136-d564-4c26-aee3-d1eaabeffa62 --><p><strong>If an adult with type 2 diabetes is unwell, consider the need to arrange hospital admission or seek specialist advice, depending on clinical judgement,</strong> taking into account the person's age, co-morbidities, risk of complications, and the presence of hyperglycaemia and/or ketosis.</p><ul><li><strong>Arrange immediate hospital admission if:</strong><ul><li>There is an immediate risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">diabetic ketoacidosis</a> (DKA), such as moderate ketonuria (2+ on urine dipstick) or ketonaemia (1.5–2.9 mmol/L) with or without hyperglycaemia, and the person cannot eat or drink.</li><li>There is an immediate risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">hyperosmolar hyperglycaemic state</a> (HHS).</li><li>There is suspected acute kidney injury (AKI) that cannot be managed in primary care. See the CKS topic on <a class="topic-reference external-reference" href="../../../acute-kidney-injury/index.html">Acute kidney injury</a> for more information.</li><li>A person treated with insulin does not show signs of clinical improvement with insulin treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a>.</li></ul></li><li><strong>Consider arranging hospital admission or seeking urgent specialist advice if:</strong><ul><li>The underlying condition is unclear.</li><li>The person is dehydrated or at risk of dehydration.</li><li>Vomiting persists beyond 2 hours.</li><li>The person and their family/carers are unable to keep the blood glucose level above 3.5 mmol/L.</li><li>The person and their family/carers are exhausted, for example due to repeated night-time waking.</li></ul></li><li><strong>If admission is not needed and the person can be managed in primary care:</strong><ul><li>Ensure that the person has written contact details of their specialist diabetes team, where appropriate.</li><li>Assess the person and manage any intercurrent illness(es), as appropriate.</li><li>Advise on the need to temporarily stop some drug treatments during periods of acute illness. See the section on <a class="topic-reference internal-reference" href="index.html#sick-day-rules">'Sick-day rules'</a> for detailed information.</li><li>Provide the person with clear, individualized advice on <a class="topic-reference internal-reference" href="index.html#sick-day-rules">'sick-day rules'</a> to manage diabetes during episodes of intercurrent illness or hyperglycaemia, and reinforce the advice regularly.<ul><li>Advise that intercurrent illness may affect blood glucose control, and there is a risk for worsening hyperglycaemia even if dietary intake is reduced.</li></ul></li><li>Ensure the person has sick day foods and drinks supplies readily accessible at home, including:<ul><li>Easily digestible foods and sugary drinks (to provide energy and to prevent further ketosis).</li><li>Over-the-counter oral rehydration therapy (ORT) sachets (to prevent dehydration).</li><li>Glucose tablets or oral gel (to prevent hypoglycaemia).</li><li>Equipment for self-monitoring of blood glucose and ketones (if appropriate). </li><li>Additional supplies of insulin (if appropriate).</li><li>A glucagon kit (if appropriate).</li><li>Note: see the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for information on blood glucose and ketone monitoring meters, glucose oral gels, and other accessories.</li></ul></li></ul></li></ul><!-- end field b598f136-d564-4c26-aee3-d1eaabeffa62 --><!-- end item cbd50e0c-1872-4d54-ae2e-65e05298a2af --></div><section aria-labelledby="sick-day-rules" class="ChapterBody-module--wrapper--2HCfk "><h4 id="sick-day-rules">'Sick-day rules'</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 72cccd7e-c6cb-4120-a30f-0d68c61c0bbe --><!-- begin field 09a1af6d-bb88-4b0a-9d24-9117b23e65c7 --><ul><li><strong>Provide 'sick-day rules' advice on managing episodes of intercurrent illness.</strong><ul><li>Advise to temporarily stop some drug treatments during acute illness. Medication may be restarted once the person is feeling better and eating and drinking for 24–48 hours, unless there is concern about renal function.<ul><li>On angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (AIIRAs), diuretics, or nonsteroidal anti-inflammatory drugs (NSAIDs) — stop treatment if there is a risk of dehydration, to reduce the risk of acute kidney injury (AKI).</li><li>On <a class="topic-reference internal-reference" href="../../prescribing-information/metformin/index.html">metformin</a> — stop treatment if there is a risk of dehydration, to reduce the risk of lactic acidosis.</li><li>On <a class="topic-reference internal-reference" href="../../prescribing-information/sulfonylureas/index.html">sulfonylureas</a> — may increase the risk of hypoglycaemia, particularly if dietary intake is reduced.</li><li>On <a class="topic-reference internal-reference" href="../../prescribing-information/sglt-2-inhibitors/index.html">SGLT-2 inhibitors</a> — check for <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">ketones</a> and stop treatment if acutely unwell and/or at risk of dehydration, due to the risk of euglycaemic DKA.</li><li>On <a class="topic-reference internal-reference" href="../../prescribing-information/glp-1-receptor-agonists/index.html">GLP-1 receptor agonists</a> — stop treatment if there is a risk of dehydration, to reduce the risk of AKI. </li></ul></li><li>If on insulin therapy, do not stop treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information.<ul><li>Advise the dose of insulin may need to be altered during periods of illness. Seek advice from the specialist diabetes team if there is uncertainty on how to adjust insulin doses.</li></ul></li><li>If <a class="topic-reference internal-reference" href="index.html#treatment-targets">self-monitoring</a> of blood glucose levels is indicated (for example on insulin therapy), advise:<ul><li>An increase in monitoring frequency may be needed, such as at least every 3–4 hours including through the night and advice to record the results.</li><li>Insulin doses may need to be adjusted, depending on the results.</li><li>To continue to self-monitor blood glucose levels carefully when feeling better, until they are back to baseline.</li><li>Seek urgent medical advice if blood glucose levels remain uncontrolled.</li></ul></li><li>Consider the need for blood or urinary <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">ketone monitoring</a>.<ul><li>This should be checked regularly, for example at least every 3–4 hours including through the night, and record the results.</li><li>If the urine ketone level is greater than 2+, or blood ketone level is greater than 3 mmol/L, the person should seek immediate medical advice. See the section on <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">When to suspect hyperglycaemic emergencies (DKA and HHS)</a> for more information.</li></ul></li><li>Advise to maintain their normal meal pattern (including fluids and carbohydrate intake) where possible if appetite is reduced.<ul><li>If unable to eat or vomiting, advise to replace normal meals with carbohydrate-containing drinks (such as milk, milkshakes, fruit juices, and sugary drinks).</li><li>If blood glucose levels are high, maintain fluid intake with sugar-free fluids.</li><li>If blood glucose levels are low, encourage regular intake of sugary fluids.</li></ul></li><li>Advise to seek urgent medical advice if the person:<ul><li>Is unable to eat or drink, is dehydrated or at risk of dehydration.</li><li>Has persistent vomiting.</li><li>Has <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a> that cannot be managed in primary care.</li></ul></li><li>The Diabetes UK information <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/illness" data-hyperlink-id="6436ab8a-5ade-4dfd-9d24-aca101132cb6">Diabetes when you're unwell</a> may be helpful.</li></ul></li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>]</p><!-- end field 09a1af6d-bb88-4b0a-9d24-9117b23e65c7 --><!-- end item 72cccd7e-c6cb-4120-a30f-0d68c61c0bbe --></div></section><section aria-labelledby="basis-for-recommendation-d44" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-d44">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d44ca4a0-926e-475e-88cf-2bba6ba644e4 --><!-- begin field 1524f541-aafc-43dc-9735-2a71d64a7f53 --><p>The recommendations on managing intercurrent illness are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], expert opinion in review articles on DKA and HHS [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>], on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>], on sick-day rules [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>], on SGLT-2 inhibitors [<a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2019</a>], and on GLP-1 receptor agonists [<a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2020</a>].</p><h5>Arranging hospital admission or seeking specialist advice</h5><ul><li>The recommendations on arranging hospital admission or seeking specialist advice are based on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>]. They are also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Managing intercurrent illness in primary care</h5><ul><li>The recommendations on the need to temporarily stop some drug treatments during intercurrent illness are based on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2020</a>]. Expert opinion in a review article notes the importance of checking blood ketone levels if a person is acutely unwell on SGLT-2 inhibitor therapy, even if blood glucose levels are not markedly raised, to assess for euglycaemic diabetic ketoacidosis (DKA) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Morris, 2020</a>].</li><li>The recommendation to provide advice on 'sick-day rules' is extrapolated from the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and is also based on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li></ul><!-- end field 1524f541-aafc-43dc-9735-2a71d64a7f53 --><!-- end item d44ca4a0-926e-475e-88cf-2bba6ba644e4 --></div></section></section><section aria-labelledby="screening-for-managing-complications" class="ChapterBody-module--wrapper--2HCfk "><h3 id="screening-for-managing-complications">How should I screen for and manage complications in adults with type 2 diabetes?</h3><section aria-labelledby="retinopathy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="retinopathy">Retinopathy</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item b723df4c-c403-4b4c-aa05-c211dbaf896a --><!-- begin field 3ba7a6e5-33f3-4061-ace8-569b23cbf037 --><p><strong>Ensure that all adults with type 2 diabetes attend for diabetic eye screening (at the time of diagnosis and at an appropriate time interval thereafter) as part of the NHS retinopathy screening programme.</strong></p><ul><li><strong>Diabetic eye screening will be offered at diagnosis and:</strong><ul><li>Every 2 years for people at low risk of sight loss (no identified diabetic retinopathy on two successive screening tests).</li><li>At least annually for all other people with diabetes.</li></ul></li><li><strong>Explain that retinal screening aims to reduce the risk of sight loss</strong> by the early detection and treatment, if needed, of sight-threatening retinopathy.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/diabetic-eye-screening" data-hyperlink-id="87d7cedb-8c8e-4050-8821-aca101574d92">Diabetic eye screening</a> may be helpful.</li></ul></li><li><strong>Arrange emergency assessment by ophthalmology if there is:</strong><ul><li>Sudden loss of vision. </li><li>Rubeosis iridis (formation of abnormal blood vessels on the anterior iris). </li><li>Pre-retinal or vitreous haemorrhage. </li><li>Suspected retinal detachment. See the CKS topic on <a class="topic-reference external-reference" href="../../../retinal-detachment/index.html">Retinal detachment</a> for more information.</li></ul></li><li><strong>Arrange an urgent referral to an ophthalmologist if there is a large sudden, unexplained reduction in visual acuity.</strong></li></ul><!-- end field 3ba7a6e5-33f3-4061-ace8-569b23cbf037 --><!-- end item b723df4c-c403-4b4c-aa05-c211dbaf896a --></div></section><section aria-labelledby="foot-problems" class="ChapterBody-module--wrapper--2HCfk "><h4 id="foot-problems">Foot problems</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7ece054b-5a0f-49f6-868a-29d43c768364 --><!-- begin field ab73ff40-1c0e-4d30-9953-0ebb24e3d72d --><p><strong>Ensure that people with type 2 diabetes have a foot check in primary care at diagnosis and at least once a year thereafter, or sooner if any foot problems arise.</strong></p><ul><li><strong>Give information on the risk of developing a diabetic foot problem</strong> at diagnosis, during reviews, and if foot problems arise, including:<ul><li>Basic foot care advice and the importance of foot care, including the need to check daily the entire surface of both feet, including areas between the toes. The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/feet" data-hyperlink-id="419ece61-9ad1-4392-b86c-aca1015d5e5f">Diabetes and foot problems</a> may be helpful.</li><li>Foot emergencies and who to contact.</li><li>Footwear advice, including to avoid shoes that are too tight, have rough edges, or uneven seams; to avoid tight-fitting socks and change socks daily.</li><li>Nail-cutting advice.</li><li>The person's current individual risk of developing a foot problem, and how to recognize foot ulcers and pre-ulcerative signs.</li></ul></li><li><strong>Ask about risk factors for foot complications:</strong><ul><li>Previous foot ulcer or lower limb amputation, peripheral arterial disease, and end-stage renal disease (ESRD). See the CKS topics on <a class="topic-reference external-reference" href="../../../peripheral-arterial-disease/index.html">Peripheral arterial disease</a> and <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information.</li><li>Symptoms of <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">peripheral neuropathy</a>.</li><li>Symptoms of peripheral arterial disease (claudication or rest pain).</li><li>Foot care, including personal care and nail cutting.</li><li>Smoking history.</li></ul></li><li><strong>Examine both feet fully for risk factors and signs of foot complications:</strong><ul><li>Peripheral neuropathy — a 10 g monofilament should be used as part of a foot sensory examination, to assess for loss of protective sensation (LOPS).<ul><li>Note: be aware that diabetic foot disease may be asymptomatic in people with neuropathy due to loss of sensation.</li></ul></li><li>Peripheral arterial disease — palpate pedal pulses and check ankle brachial pressure index (ABPI), if indicated. See the CKS topic on <a class="topic-reference external-reference" href="../../../peripheral-arterial-disease/index.html">Peripheral arterial disease</a> for more information.<ul><li>Note: interpret ABPI results with caution, as calcification of pedal arteries may falsely elevate results.</li></ul></li><li>Ulceration — may be neuropathic (most commonly affecting plantar surface or areas overlying a bony deformity); neuroischaemic or ischaemic (most commonly affecting the tips of toes or lateral border of the foot).</li><li>Pre-ulcerative signs — callus, fissures, oedema, or blister formation.</li><li>Infection and/or inflammation (redness, warmth, induration, and pain/tenderness) or purulent discharge. See the CKS topics on <a class="topic-reference external-reference" href="../../../paronychia-acute/index.html">Paronychia - acute</a> and <a class="topic-reference external-reference" href="../../../cellulitis-acute/index.html">Cellulitis - acute</a> for more information.<ul><li>Note: typical findings may be reduced due to the presence of neuropathy and/or ischaemia.</li></ul></li><li>Foot deformity (such as claw or hammer toes), large bony prominences, limited joint mobility.</li><li>Gangrene.</li><li>Charcot arthropathy — an acute, localized inflammatory condition that may lead to varying degrees and patterns of bone destruction, subluxation, dislocation, and deformity.</li><li>Footwear — ill-fitting, inadequate, or lack of.<ul><li>If there is evidence of foot deformity and/or abnormal loading of the foot (for example callus formation), consider referral to podiatry for footwear advice and possible orthoses, specialist footwear, or splints.</li></ul></li><li>Foot hygiene — improperly cut toenails, thickened or ingrown nails, unwashed feet, superficial fungal infection, unclean socks. See the CKS topics on <a class="topic-reference external-reference" href="../../../fungal-skin-infection-foot/index.html">Fungal skin infection - foot</a> and <a class="topic-reference external-reference" href="../../../fungal-nail-infection/index.html">Fungal nail infection</a> for more information.</li></ul></li><li><strong>Following foot examination, assess the person's foot ulceration risk category:</strong><ul><li>Low risk — no risk factors present.</li><li>Moderate risk — one risk factor present.</li><li>High risk — previous ulceration or amputation, on renal replacement therapy, or more than one risk factor present.</li><li>Active foot problem — ulceration; spreading infection; critical limb ischaemia; gangrene; suspected acute Charcot arthropathy (or an unexplained hot, red, swollen foot with or without pain). </li></ul></li><li><strong>Arrange management depending on the person's foot ulceration risk category:</strong><ul><li>For people with a potentially limb- or life-threatening <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complication</a> — arrange immediate referral to acute services.</li><li>For people with a non-limb- or life-threatening active foot problem — arrange urgent referral to the foot protection service (within 1 working day).</li><li>For people at high risk — arrange referral to the foot protection service to be seen within 2–4 weeks.</li><li>For people at moderate risk — arrange referral to the foot protection service to be seen within 6–8 weeks.</li><li>For people at low risk:<ul><li>Continue annual foot checks.</li><li>Reinforce the importance of good foot care.</li><li>Explain the risk of progression to moderate- or high-risk categories without appropriate foot care.</li></ul></li></ul></li><li><strong>Advise on the need for regular foot checks, depending on the risk of developing a foot problem:</strong><ul><li>Annually — for people who are at low risk. </li><li>Frequently (for example every 3–6 months) — for people who are at moderate risk. </li><li>More frequently (for example every 1–2 months) — for people who are at high risk, if there is no immediate concern. </li><li>Very frequently (for example every 1–2 weeks) — for people who are at high risk, if there is immediate concern. </li><li>Note: more frequent reassessments should be considered for people who are unable to check their own feet.</li></ul></li></ul><!-- end field ab73ff40-1c0e-4d30-9953-0ebb24e3d72d --><!-- end item 7ece054b-5a0f-49f6-868a-29d43c768364 --></div></section><section aria-labelledby="diabetic-kidney-disease" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diabetic-kidney-disease">Diabetic kidney disease</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7893fe92-9b42-4e9f-9705-a09a227075f4 --><!-- begin field 1175ccbd-3f1b-4314-b68f-0db99a434a2f --><p><strong>Ensure all adults with type 2 diabetes have annual screening for diabetic kidney disease. </strong></p><ul><li><strong>To assess for diabetic kidney disease:</strong><ul><li>Arrange an early morning first-void urine sample for assessment of microalbuminuria by estimation of the albumin:creatinine ratio (ACR). </li><li>Measure serum creatinine at the same time to calculate the estimated glomerular filtration rate (eGFR).</li></ul></li><li><strong>Make a diagnosis of chronic kidney disease (CKD) and manage appropriately if there is:</strong><ul><li>A persistent reduction in kidney function, if the eGFR is less than 60 mL/min/1.73 m<sup>2</sup> for 3 months or more, <em>and/or</em></li><li>Persistent proteinuria with urine ACR greater than 3 mg/mmol, for 3 months or more. See the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information.</li></ul></li><li><strong>If CKD is identified on testing:</strong><ul><li>Classify the stage of CKD and arrange ongoing monitoring and management, depending on the severity.<ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information on monitoring, management, and referral criteria.</li></ul></li><li>Aim to optimize <a class="topic-reference internal-reference" href="index.html#treatment-targets">blood glucose control</a>, <a class="topic-reference internal-reference" href="index.html#lipid-modification">lipid levels</a>, and <a class="topic-reference internal-reference" href="index.html#antihypertensive-treatment">blood pressure</a> to reduce the risk of progressive kidney disease.</li><li>Ensure the person is aware of the <a class="topic-reference internal-reference" href="index.html#sick-day-rules">'sick-day rules'</a> and which medications, if any, to temporarily stop if there is intercurrent illness or dehydration, to reduce the risk of acute kidney injury (AKI). See the CKS topic on <a class="topic-reference external-reference" href="../../../acute-kidney-injury/index.html">Acute kidney injury</a> for more information.</li><li>All people with CKD stage 3 or more and/or confirmed urine microalbuminuria, should be offered atorvastatin 20 mg once daily, irrespective of lipid profile. See the section on <a class="topic-reference internal-reference" href="index.html#lipid-modification">Lipid modification</a> for more information.</li><li>All people with CKD stage 3 or more and/or confirmed urine microalbuminuria, should be offered an angiotensin-converting enzyme (ACE) inhibitor if not contraindicated. See the section on <a class="topic-reference internal-reference" href="index.html#antihypertensive-treatment">Antihypertensive treatment</a> for more information.</li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/kidneys_nephropathy" data-hyperlink-id="bcd081f4-b284-49ed-9361-aca1016244b8">Diabetic nephropathy (kidney disease)</a> may be helpful.</li></ul></li></ul><!-- end field 1175ccbd-3f1b-4314-b68f-0db99a434a2f --><!-- end item 7893fe92-9b42-4e9f-9705-a09a227075f4 --></div></section><section aria-labelledby="cardiovascular-risk-factors" class="ChapterBody-module--wrapper--2HCfk "><h4 id="cardiovascular-risk-factors">Cardiovascular risk factors</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9fb73ff5-0673-4e57-beef-a4c2abccc4d9 --><!-- begin field a9f739be-4450-4593-b2d7-7eec42a5ed9e --><ul><li><strong>Ensure all people with type 2 diabetes have their cardiovascular risk factors assessed at least annually, including:</strong><ul><li>Smoking status — offer advice on smoking cessation, if needed. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information.</li><li>Blood glucose control. See the section on <a class="topic-reference internal-reference" href="index.html#treatment-targets">Treatment targets</a> for more information.</li><li>Blood pressure. See the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information on diagnosing hypertension, and the section on <a class="topic-reference internal-reference" href="index.html#antihypertensive-treatment">Antihypertensive treatment</a> for more information on management.</li><li>Albuminuria. See the section on <a class="topic-reference internal-reference" href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a> for more information.</li><li>Full lipid profile (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and triglycerides). See the section on <a class="topic-reference internal-reference" href="index.html#lipid-modification">Lipid modification</a> for more information.</li><li>Family history of cardiovascular disease (CVD).</li><li>Measure height, weight, and waist circumference, and calculate the body mass index (BMI). Offer management for people who are overweight or obese. See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li><strong>Ensure people with CVD risks factors are managed appropriately.</strong> See the section on <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">Lifestyle advice</a> and the CKS topic on <a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a> for more information.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/cardiovascular_disease" data-hyperlink-id="b5842727-0ffd-4b05-924e-aca10164a106">Diabetes and heart disease</a> may be helpful.</li></ul></li></ul><!-- end field a9f739be-4450-4593-b2d7-7eec42a5ed9e --><!-- end item 9fb73ff5-0673-4e57-beef-a4c2abccc4d9 --></div></section><section aria-labelledby="peripheral-autonomic-neuropathy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="peripheral-autonomic-neuropathy">Peripheral and autonomic neuropathy</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 789065c3-99c6-4f0a-8843-4008f7b44204 --><!-- begin field 3a696baf-8db2-4402-8b52-ac8300f0641b --><ul><li><strong>Screen for symptoms of peripheral neuropathy by asking about:</strong><ul><li>Painful neuropathy symptoms of numbness, burning or shooting pain, tingling and/or paraesthesia of the hands and/or feet, typically in a stocking and glove distribution, often at night, which may be relieved by activity.<ul><li>Painful neuropathy of the foot may initially affect the toes and outer edges of the feet.</li><li>If suspected, see the CKS topic on <a class="topic-reference external-reference" href="../../../neuropathic-pain-drug-treatment/index.html">Neuropathic pain - drug treatment</a> for more information on management options.</li></ul></li><li>There may be associated motor neuropathy, such as muscle weakness, wasting, cramps and/or twitching, which may cause eventual deformity.<ul><li>If there is hand involvement, it may affect fine motor skills over time.</li><li>If there is foot involvement, consider referral to podiatry for footwear advice and possible orthoses, specialist footwear, or splints. See the section on <a class="topic-reference internal-reference" href="index.html#foot-problems">Foot problems</a> for more information on screening for peripheral neuropathy of the feet.</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/nerves_neuropathy" data-hyperlink-id="9686fb31-b78f-4469-9451-aca200ad2cdc">Diabetic neuropathy</a> may be helpful.</li></ul></li><li><strong>Assess for symptoms or signs suggesting autonomic neuropathy,</strong> which can affect multiple systems and typically has a gradual, progressive onset:<br><ul><li>Postural hypotension (may be defined as a drop in systolic blood pressure of more than 30 mmHg when changing from a lying to a standing position, without any increase in heart rate).<ul><li>Ask about drug treatment with tricyclic antidepressants or antihypertensive drugs that may contribute to symptoms.</li><li>Consider arranging referral to the specialist diabetes team if symptoms are troublesome and affecting daily functioning.</li></ul></li><li>'Diabetic gastroparesis' suggested by delayed gastric emptying, bloating, nausea, and post-prandial vomiting.<ul><li>Advise a small-particle-size diet (mashed or pureed food) for symptom relief of delayed gastric emptying. Consider arranging referral to a gastroenterologist or the specialist diabetes team for consideration of treatment with a prokinetic drug.</li></ul></li><li>Lower gastrointestinal involvement may cause lower abdominal pain, unexplained diarrhoea (may be nocturnal), and faecal incontinence.</li><li>Unexplained urinary symptoms such as hesitancy, reduced frequency, inadequate bladder emptying, and urinary retention, if other possible causes have been excluded. See the CKS topics on <a class="topic-reference external-reference" href="../../../luts-in-men/index.html">LUTS in men</a>, <a class="topic-reference external-reference" href="../../../urinary-tract-infection-lower-men/index.html">Urinary tract infection (lower) - men</a>, and <a class="topic-reference external-reference" href="../../../urinary-tract-infection-lower-women/index.html">Urinary tract infection (lower) - women</a> for more information.<ul><li>If suspected, consider arranging referral to the specialist diabetes team or urology for advice on management.</li></ul></li><li>Sexual dysfunction, erectile dysfunction, and/or retrograde ejaculation.<ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../erectile-dysfunction/index.html">Erectile dysfunction</a> for more information on diagnosis and management.</li><li>The Diabetes UK patient resources <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/sexual-problems-women" data-hyperlink-id="18b672a1-9a32-487f-a7c5-aca200ad2cdc">Diabetes and sexual problems - in women</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/sexual-problems-men" data-hyperlink-id="29bb1fd6-0054-4b68-9008-aca200ad2cdc">Diabetes and sexual problems - in men</a> may be helpful.</li></ul></li><li>Sweating abnormalities, such as reduced sweating in a stocking and glove distribution.</li><li>Impaired awareness of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a>.<ul><li>If suspected, arrange referral to the specialist diabetes team for advice on management.</li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/hypos" data-hyperlink-id="8de51840-1c1f-47d5-b64a-aca200ad2cdc">What is a hypo?</a> may be helpful.</li></ul></li></ul></li></ul><!-- end field 3a696baf-8db2-4402-8b52-ac8300f0641b --><!-- end item 789065c3-99c6-4f0a-8843-4008f7b44204 --></div></section><section aria-labelledby="basis-for-recommendation-594" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-594">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5949158c-77fe-46b1-8a7a-ec1f5af541ba --><!-- begin field b18b6e84-5f3c-47b9-a91f-7769fa4a8bb7 --><p>The recommendations on screening for complications are largely based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Type 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], <em>Diabetic foot problems: prevention and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>], and <em>Hypertension in adults: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>]; the joint European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) publication <em>ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>]; the summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA) <em>Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>]; the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) <em>Management of hyperglycemia in type 2 diabetes, 2018</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>]; the International Working Group on the Diabetic Foot (IWGDF) publication <em>Practical guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaper, 2020</a>]; the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Microvascular and macrovascular complications in children and adolescents</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Donoghue, 2018</a>]; the Public Health England (PHE) publication <em>Diabetic eye screening extended intervals: what will people need to know?</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2020</a>]; and expert opinion in review articles on diabetic foot care [<a class="bibliography-reference internal-reference" href="../../references/index.html">Baker, 2020</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Dutta, 2020</a>], on diabetic kidney disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">Winocour, 2020</a>], on diabetic neuropathy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Guttormsen, 2017</a>], and on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</p><h5>Screening for retinopathy</h5><ul><li>The recommendation on the need for diabetic eye screening as part of the NHS retinopathy screening programme is based on the NICE clinical guideline on type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>]. Expert opinion in a review article notes that early detection and treatment of retinopathy is vital to stop the progression of the stages of retinopathy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The information on the planned extension of time interval from annual to 2-yearly screening for people at low risk of sight loss and sight-threatening retinopathy is based on evidence from a large observational study reviewed by the UK National Screening Committee [<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2020</a>].</li><li>The recommendations on when to arrange emergency ophthalmology assessment are based on the NICE clinical guideline on type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].</li><li>The recommendation on when to arrange urgent referral to ophthalmology is based on the NICE clinical guideline on type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].</li></ul><h5>Screening for foot problems</h5><ul><li>The recommendations on providing information and advice about foot care are largely based on the NICE clinical guideline on diabetic foot problems [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>].</li><li>The IWGDF publication notes that foot education is important to improve foot self-care, knowledge, and self-protective behaviour in prevention of diabetic foot ulcers. It highlights the importance of identifying the at-risk foot, regularly inspecting and examining the at-risk foot, ensuring routine wearing of appropriate footwear, and treating risk factors for foot ulceration [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaper, 2020</a>].<ul><li>Inappropriate footwear is a major cause of foot trauma that can predispose to the development of foot ulcers.</li></ul></li><li>The recommendations on history taking and foot examination are based on the IWGDF publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaper, 2020</a>] and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Baker, 2020</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Dutta, 2020</a>].<ul><li>The information that diabetic foot disease may be asymptomatic in people with neuropathy due to loss of sensation is based on the IWGDF publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaper, 2020</a>] and is supported by expert opinion in review articles that note that symptoms of peripheral arterial disease may not be present due to neuropathy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Baker, 2020</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Dutta, 2020</a>]. Peripheral neuropathy and loss of protective sensation may contribute to the development of foot ulceration due to reduced proprioception and balance [<a class="bibliography-reference internal-reference" href="../../references/index.html">Dutta, 2020</a>].</li><li>The information on the limitations of interpreting ankle brachial pressure index (ABPI) measurements in people with diabetes is based on the NICE clinical guideline on diabetic foot problems [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Dutta, 2020</a>].</li><li>The information that typical findings of infection or inflammation may be reduced due to the presence of neuropathy and/or ischaemia is based on the IWGDF publication [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaper, 2020</a>].</li></ul></li><li>The information on assessing foot ulceration risk categories, subsequent management, and timescales of referral is based on the NICE clinical guideline on diabetic foot problems [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>].<ul><li>The recommendation to arrange more frequent reassessments if a person is unable to check their own feet is based on the NICE clinical guideline on diabetic foot problems [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>].</li></ul></li></ul><h5>Screening for diabetic kidney disease</h5><ul><li>The recommendation that people with diabetes should be screened annually for diabetic kidney disease is extrapolated from the joint ESC/EASD guidelines, based on data derived from multiple randomized controlled trials (RCTs) or meta-analyses. Routine assessment for microalbuminuria helps to identify people at risk of CKD and/or cardiovascular disease (CVD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li><li>This approach is supported by expert opinion in a review article, which notes that a combination of estimated glomerular filtration rate (eGFR) and urine albumin:creatinine ratio (ACR) testing improves risk stratification and diagnostic accuracy of identifying chronic kidney disease (CKD) in people with diabetes, and each provide an independent measure for risk of adverse renal and cardiovascular (CV) outcomes. It highlights that elevated urine ACR is an early marker for renal damage and risk of progressive disease, irrespective of the eGFR level [<a class="bibliography-reference internal-reference" href="../../references/index.html">Winocour, 2020</a>]. The joint ABCD/RA guidance notes that urinary ACR is more sensitive for the detection of diabetic nephropathy (glomerular damage-causing albuminuria in the absence of other causes) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>].</li><li>The joint ABCD/RA guidance highlights that CKD is an independent and major risk factor for the development of CVD in people with diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>]. Expert opinion in a review article also notes that early recognition and treatment of diabetic nephropathy may prevent or delay the progression of renal disease, reduce the risk of complications, and lower the risk of CVD. There is a need for a higher frequency of renal monitoring in higher risk categories of diabetic kidney disease, as there is a greater risk of CVD and progression of CKD [<a class="bibliography-reference internal-reference" href="../../references/index.html">Winocour, 2020</a>].</li><li>The recommendation to advise the person that optimal blood glucose and blood pressure control may slow any decline in kidney function is based on the joint ESC/EASD guidelines, which note that tight blood glucose control can reduce the risk of microvascular complications, based on data derived from multiple RCTs or meta-analyses [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>]. This approach is supported by expert opinion in a review article, which notes that optimization of blood glucose, lipids, and blood pressure may reduce CV risk [<a class="bibliography-reference internal-reference" href="../../references/index.html">Winocour, 2020</a>].</li><li>The recommendations on the importance of 'sick-day rules' and temporarily stopping medication if there is intercurrent illness is based on expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The recommendation that all people with CKD stage 3 or more and/or confirmed urine microalbuminuria should be offered a statin is based on the joint ABCD/RA guidance [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>].</li><li>The recommendation that all people with CKD stage 3 or more and/or confirmed urine microalbuminuria should be offered an angiotensin-converting enzyme (ACE) inhibitor if not contraindicated, is based on expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li></ul><h5>Screening for cardiovascular disease (CVD) risk</h5><ul><li>The recommendations on annual screening for CVD are extrapolated from the NICE clinical guideline on hypertension, which recommends blood pressure is checked at least annually in adults with type 2 diabetes without previously diagnosed hypertension or renal disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>]. In addition, the consensus report by the ADA/EASD recommends screening for CV risk factors [<a class="bibliography-reference internal-reference" href="../../references/index.html">Davies, 2018</a>].</li><li>The recommendation on the need for a full lipid profile at least annually is extrapolated from the joint ABCD/RA guidance [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>].</li></ul><h5>Screening for peripheral and autonomic neuropathy</h5><ul><li>The information on the clinical features of peripheral neuropathy is extrapolated from the ISPAD clinical practice consensus guidelines on complications in diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Donoghue, 2018</a>] and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Guttormsen, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Baker, 2020</a>].</li><li>The information on the possible multiple presentations of autonomic neuropathy is based on the NICE clinical guideline on type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], and is also extrapolated from the ISPAD clinical practice consensus guidelines on complications in diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Donoghue, 2018</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Guttormsen, 2017</a>].<ul><li>The definition of postural hypotension is based on expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Guttormsen, 2017</a>].</li><li>The information on the increased risk of postural hypotension due to the combined effects of sympathetic autonomic neuropathy and some drug treatments is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].</li><li>The recommendations on management of suspected gastroparesis are based on the NICE clinical guideline, which recommends alternating treatment with erythromycin and metoclopramide [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>].</li></ul></li></ul><!-- end field b18b6e84-5f3c-47b9-a91f-7769fa4a8bb7 --><!-- end item 5949158c-77fe-46b1-8a7a-ec1f5af541ba --></div></section></section><section aria-labelledby="managing-cardiovascular-risk" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-cardiovascular-risk">How should I manage cardiovascular risk in an adult with type 2 diabetes?</h3><section aria-labelledby="antihypertensive-treatment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="antihypertensive-treatment">Antihypertensive treatment</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 70455a66-0f27-45c5-93d6-983fceae62c7 --><!-- begin field 1241853c-1505-406c-8baf-c86ee39e050a --><p><strong>If the person is already on </strong> <strong>antihypertensive drug treatment:</strong></p><ul><li>Reinforce the importance of <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">lifestyle advice</a>.</li><li>Review blood pressure control and drug treatments used. See the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information on monitoring blood pressure and drug treatment options.<ul><li>Amend treatment if there is uncontrolled blood pressure and/or drug treatment is not appropriate due to microvascular or metabolic <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a>.</li></ul></li><li>Aim to maintain blood pressure below the following targets, depending on the person's age, risks and benefits of treatment, and co-morbidities (including frailty and multimorbidity):<br><ul><li>Aged under 80 years — reduce clinic blood pressure to below 140/90 mmHg; ambulatory or home blood pressure monitoring (ABPM/HBPM) to below 135/85 mmHg.</li><li>Aged 80 years and over — reduce clinic blood pressure to below 150/90 mmHg; ambulatory or home blood pressure monitoring to below 145/85 mmHg.</li><li>With known chronic kidney disease (CKD) — reduce blood pressure to systolic less than 130 mmHg (target range 120–129 mmHg) and diastolic less than 80 mmHg. See the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information.</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/blood-pressure" data-hyperlink-id="60ff48c9-ff30-4a1c-88bb-aca2015eec53">Diabetes and blood pressure</a> may be helpful.</li></ul><p><strong>If the person has newly diagnosed hypertension:</strong></p><ul><li>Reinforce the importance of <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">lifestyle advice</a>.</li><li>Confirm a diagnosis of hypertension in a person with clinic blood pressure of 140/90 mmHg or higher <em>and</em> ABPM daytime average or HBPM average of 135/85 mmHg or higher.<ul><li>Measure standing as well as seated blood pressure.</li><li>Classify the person's stage of hypertension.</li><li>Assess whether antihypertensive treatment is needed, depending on the stage of hypertension, person's age, estimated 10-year cardiovascular risk, evidence of target organ damage, and co-morbidities (including frailty or multimorbidity).</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information on stages of hypertension.</li></ul></li><li>If antihypertensive drug treatment is indicated:<ul><li>Assess the person's treatment goals and preferences and explain the risks and benefits of drug treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information on drug treatment options.</li><li>Offer a generic angiotensin-converting enzyme (ACE) inhibitor or angiotensin-II receptor antagonist (AIIRA) to all adults (of any age or ethnic origin).<ul><li>For adults of black African or African-Caribbean origin, consider an AIIRA in preference to an ACE inhibitor.</li><li>If an ACE inhibitor is not tolerated, offer an AIIRA.</li><li>Do not combine an ACE inhibitor with an AIIRA to treat hypertension.</li></ul></li><li>Offer a calcium-channel blocker (CCB) or thiazide-like diuretic in addition to an ACE inhibitor or AIIRA, if hypertension is not controlled by monotherapy. </li><li>Offer a combination of an ACE inhibitor or AIIRA, a CCB <em>and</em> a thiazide-like diuretic if hypertension remains uncontrolled.  </li><li>If hypertension is not controlled with optimal tolerated doses of an ACE inhibitor or an AIIRA, plus a CCB and a thiazide-like diuretic:<ul><li>Before considering further treatment, confirm elevated clinic blood pressure measurements using ABPM or HBPM, assess for postural hypotension, and discuss adherence with treatment. </li><li>Consider adding a fourth antihypertensive drug, or seek specialist advice, for people with confirmed resistant hypertension. See the CKS topic on <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a> for more information.</li><li>Seek specialist advice if blood pressure remains uncontrolled with optimal tolerated doses of four antihypertensive drugs.</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/blood-pressure" data-hyperlink-id="6584a975-1dea-4001-b9ee-aca2015eec53">Diabetes and blood pressure</a> may be helpful.</li></ul></li></ul><!-- end field 1241853c-1505-406c-8baf-c86ee39e050a --><!-- end item 70455a66-0f27-45c5-93d6-983fceae62c7 --></div></section><section aria-labelledby="lipid-modification" class="ChapterBody-module--wrapper--2HCfk "><h4 id="lipid-modification">Lipid modification</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8bc3b989-be8f-4230-9f65-523350a275e0 --><!-- begin field c00ca1b2-faef-49e1-986c-34cdd8b55627 --><ul><li><strong>If an adult with type 2 diabetes does <em>not</em> have established cardiovascular disease</strong> <strong>(CVD), offer atorvastatin 20 mg once daily for primary prevention of CVD if:</strong><ul><li> The person is aged 84 years and younger, and their estimated 10-year risk of developing CVD is 10% or more.<ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a> for more information on assessing CVD risk and using the QRISK assessment tool.</li></ul></li><li>The person is 85 years of age or older, taking into account the person's preferences, benefits and risks of treatment, and co-morbidities (including frailty and multimorbidity).</li><li>The person has a diagnosis of chronic kidney disease (CKD).<ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a> for more information.</li></ul></li><li>Note: see the CKS topic on <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for detailed information on baseline blood tests, initiating statin treatment, and monitoring.</li></ul></li><li><strong>If an adult with type 2 diabetes has established CVD, offer atorvastatin 80 mg once daily for secondary prevention of CVD.</strong><ul><li>See the CKS topics on <a class="topic-reference external-reference" href="../../../angina/index.html">Angina</a>, <a class="topic-reference external-reference" href="../../../stroke-tia/index.html">Stroke and TIA</a>, and <a class="topic-reference external-reference" href="../../../peripheral-arterial-disease/index.html">Peripheral arterial disease</a> for more information.</li><li>Note: see the CKS topic on <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for detailed information on baseline blood tests, initiating statin treatment, and monitoring.</li></ul></li><li><strong>Aim for a greater than 40% reduction in non-HDL cholesterol.</strong><ul><li>Consider up-titration of the atorvastatin dose to achieve this target, if appropriate, depending on clinical judgement. See the CKS topic on <a class="topic-reference external-reference" href="../../../lipid-modification-cvd-prevention/index.html">Lipid modification - CVD prevention</a> for more information.</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/managing-other-medical-conditions/cholesterol-and-diabetes" data-hyperlink-id="71542523-9657-4438-9b47-aca300b10470">Cholesterol and diabetes</a> may be helpful.</li></ul><!-- end field c00ca1b2-faef-49e1-986c-34cdd8b55627 --><!-- end item 8bc3b989-be8f-4230-9f65-523350a275e0 --></div></section><section aria-labelledby="antiplatelet-treatment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="antiplatelet-treatment">Antiplatelet treatment</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2599a469-84be-4104-a2a8-025bb7e04e32 --><!-- begin field 527bbf83-a38a-45b4-b8e5-e2edffc505ab --><ul><li><strong>Do not routinely offer antiplatelet treatment (aspirin or clopidogrel) for the primary prevention of cardiovascular disease (CVD) in adults with type 2 diabetes.</strong><ul><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../antiplatelet-treatment/index.html">Antiplatelet treatment</a> for more information on the primary and secondary prevention of CVD in adults with type 2 diabetes.</li></ul></li></ul><!-- end field 527bbf83-a38a-45b4-b8e5-e2edffc505ab --><!-- end item 2599a469-84be-4104-a2a8-025bb7e04e32 --></div></section><section aria-labelledby="basis-for-recommendation-c62" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-c62">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c62d449e-e2ce-403d-a9cf-b93f4ccea5d0 --><!-- begin field 81288b38-6070-49a2-80fa-67f88df023b6 --><p>The recommendations on managing cardiovascular risk are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>T</em><em>ype 2 diabetes in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>], <em>Hypertension in adults: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>], <em>Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], and <em>Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>]; the joint European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) publication <em>ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>]; the summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA) <em>Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>]; and expert opinion in review articles on diabetic kidney disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lewis, 2019</a>], on aspirin use [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kenny, 2018</a>], and on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</p><h5>Antihypertensive treatment</h5><ul><li>The joint ESC/EASD guidelines note that optimal blood pressure control reduces the risk of microvascular and macrovascular complications of diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>]. This is supported by expert opinion in a review article that notes that uncontrolled or suboptimally controlled hypertension can increase the risk of complications such as diabetic retinopathy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>].</li><li>The recommendations on blood pressure measurement, monitoring, and targets are largely based on the NICE clinical guidelines on hypertension<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>] and chronic kidney disease (CKD) [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015a</a>], and the joint ESC/EASD guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].<ul><li>The recommendation to reinforce lifestyle advice is based on the joint ESC/EASD guidelines.</li><li>The recommendation to use clinical judgement when offering antihypertensive treatment for people with frailty or multimorbidity is based on the clinical experience of the guideline development group, which noted this group are at increased risk of adverse events and derive less potential benefit from strict blood pressure targets.</li><li>NICE did not find evidence that blood pressure targets in people with type 2 diabetes should be different to those for people without diabetes, with limited evidence suggesting that lower blood pressure targets did not reduce the rate of cardiovascular (CV) events<em>.</em></li><li>The recommendation on blood pressure targets if a person has CKD is based on the NICE clinical guideline on CKD.</li><li>The recommendation to measure standing as well as seated blood pressure in people with type 2 diabetes is based on the clinical expertise of the NICE guideline development group, which noted that people with type 2 diabetes are at increased risk of postural hypotension. They may experience adverse events if a sitting or lying blood pressure is used for monitoring, because this measurement would overestimate daytime blood pressure and result in overtreatment, increasing the potential risk for falls<em>.</em></li></ul></li><li>The recommendations on antihypertensive treatment options and monitoring are based on the NICE clinical guideline on hypertension<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019a</a>], the joint ESC/EASD guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lewis, 2019</a>].<ul><li>The recommendation to offer an ACE inhibitor or AIIRA for initial treatment of hypertension is based on the clinical expertise of the NICE guideline development group, which felt these two drug classes were clinically equivalent and cost equivalent. This approach is supported by the joint ESC/EASD guidelines, which note that ACE inhibitors and AIIRAs are also the preferred antihypertensive drugs in people with confirmed proteinuria or microalbuminuria, and reductions in albuminuria are associated with 'renoprotection', based on data derived from multiple randomized controlled trials (RCTs) or meta-analyses [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>]. Furthermore, expert opinion in a review article notes that these drugs reduce intraglomerular pressure and have renoprotective properties beyond their antihypertensive effect alone [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lewis, 2019</a>].</li><li>The recommendation not to combine ACE inhibitor and AIIRA therapy is based on the NICE clinical guideline on hypertension and the joint ESC/EASD guidelines.</li><li>The joint ESC/EASD guidelines recommend that home blood pressure self-monitoring should be considered in people with type 2 diabetes, especially if they are taking combination antihypertensive treatment, based on limited evidence and consensus opinion.</li></ul></li><li>CKS notes that, in contrast to the NICE clinical guideline, the joint ESC/EASD guidelines have different blood pressure targets for people on treatment, and also recommend dual antihypertensive therapy as first-line treatment, based on data derived from multiple RCTs or meta-analyses [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li></ul><h5>Lipid modification</h5><ul><li>The recommendations on risk assessment and offering lipid-lowering therapy for primary and secondary prevention of cardiovascular disease (CVD) are largely based on the NICE clinical guideline on lipid modification [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>], the joint Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA) guidance [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>], and the joint ESC/EASD guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].<br><ul><li>The NICE guideline development group considered people aged 85 years and older to be at high risk of CVD by virtue of age alone, and therefore have a greater likelihood of clinical benefit from lipid-modification therapy without the need for a formal risk assessment. In addition, the QRISK assessment tool has an upper age limit of 84 years.</li><li>People with CKD are at higher risk of CVD, and NICE recommends they should be offered statin treatment for primary prevention. This approach is supported by the joint ABCD/RA guidance. CKS notes that the joint ABCD/RA guidance differs from the NICE clinical guideline in also recommending lipid-lowering therapy for all people with type 2 diabetes aged more than 40 years (irrespective of lipid status) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>].</li><li>For people with established CVD, the guideline development group recommended lipid-modification therapy without the need for a formal risk assessment, because they are at increased risk of recurrence of CVD.</li><li>The joint ESC/EASD guidelines note that statins effectively prevent CV events and reduce CV mortality, and their use is associated with a limited number of adverse events. It therefore recommends the use of statins first line for lipid-lowering treatment for people with diabetes and high LDL-C levels, based on data derived from multiple RCTs or meta-analyses [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li></ul></li><li>The recommendation on choice of statin therapy is based on the NICE clinical guideline on lipid modification [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>].<ul><li>NICE reviewed the evidence from 34 randomized studies comparing UK licensed statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin) with placebo for the prevention of CVD in adults (three studies included people with type 2 diabetes).<ul><li>Good-quality evidence showed that compared with placebo, statins have a beneficial effect on non-fatal myocardial infarction. There was also a beneficial effect on all-cause mortality and CV mortality, but the effect sizes were too small to be clinically significant. There was no clinical difference between statins and placebo for stroke prevention.</li><li>It found high-intensity statin treatment is the most clinically- and cost-effective option for the primary and secondary prevention of CVD in people with type 2 diabetes.</li></ul></li><li>NICE did not identify any head-to-head trials on the effectiveness of the high-intensity statins (in terms of reducing clinical endpoints) in people with or without type 2 diabetes. The guideline development group assumed equivalent effectiveness between all high-intensity statins, and recommended atorvastatin first line due to its favourable adverse effect profile and cost.</li><li>NICE did not make specific recommendations on the choice and dose of statin for the secondary prevention of CVD in people with type 2 diabetes. CKS has therefore extrapolated this recommendation from the NICE recommendations for the secondary prevention of CVD in the general population.</li></ul></li><li>The recommendation to aim for a greater than 40% reduction in non-HDL cholesterol and consider up-titration of the atorvastatin dose to achieve this target, depending on clinical judgement, is based on the NICE clinical guideline on lipid modification [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>].<br><ul><li>CKS notes that the joint ESC/EASD guidelines recommend different lipid LDL-C reductions and targets for people with type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>]. Similarly, the joint ABCD/RA guidance recommends aiming to reduce TC to 4 mmol/L, LDL cholesterol to 2 mmol/L, and non-HDL cholesterol to 2.5 mmol/L [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mark, 2017</a>].</li></ul></li></ul><h5>Antiplatelet treatment</h5><ul><li>The recommendation not to offer antiplatelet treatment for the primary prevention of CVD in adults with type 2 diabetes is based on the NICE clinical guideline on type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kenny, 2018</a>].<ul><li>NICE found low- to very-low quality evidence suggesting an increased risk of harm (including bleeding events) associated with the use of aspirin, and there was uncertainty around whether aspirin reduced the incidence of cardiovascular events. The guideline development group concluded that antiplatelet therapy would not be of sufficient benefit for the primary prevention of CVD in the majority of people with type 2 diabetes. It was felt that although reducing the risk of CVD and mortality are important in improving life expectancy and quality of life, the relative impact of adverse events associated with the off-label use of aspirin and clopidogrel for primary prevention was also important in determining the relative safety and acceptability of antiplatelet treatment.</li><li>This approach is supported by expert opinion in a review article that notes that aspirin should not be used for primary prevention, as the risks of adverse effects such as major bleeding events outweigh the benefits of CV risk reduction [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kenny, 2018</a>].</li></ul></li><li>CKS notes that the joint ESC/EASD guidelines differ from the NICE recommendations, and state that the use of aspirin may be considered for primary prevention in people with diabetes at very high/high risk of CVD if there are no contraindications, based on data derived from multiple RCTs or meta-analyses. It acknowledges that the role of aspirin for primary prevention in this group is less clear than its use for secondary prevention in people with established CVD [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cosentino, 2020</a>].</li></ul><!-- end field 81288b38-6070-49a2-80fa-67f88df023b6 --><!-- end item c62d449e-e2ce-403d-a9cf-b93f4ccea5d0 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/diabetes-type-2/management/management-adults/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>